WO2000061752A2 - Modified complement system regulators - Google Patents
Modified complement system regulators Download PDFInfo
- Publication number
- WO2000061752A2 WO2000061752A2 PCT/US2000/009288 US0009288W WO0061752A2 WO 2000061752 A2 WO2000061752 A2 WO 2000061752A2 US 0009288 W US0009288 W US 0009288W WO 0061752 A2 WO0061752 A2 WO 0061752A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ccp
- amino acids
- lhr
- crl
- binding
- Prior art date
Links
- 230000004154 complement system Effects 0.000 title description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 92
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 84
- 150000001413 amino acids Chemical class 0.000 claims description 107
- 241001465754 Metazoa Species 0.000 claims description 19
- 101100273664 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ccp-1 gene Proteins 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 230000024203 complement activation Effects 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 14
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 159
- 238000009739 binding Methods 0.000 abstract description 159
- 238000006467 substitution reaction Methods 0.000 abstract description 30
- 230000003993 interaction Effects 0.000 abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 16
- 230000001965 increasing effect Effects 0.000 abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 abstract description 10
- 238000002703 mutagenesis Methods 0.000 abstract description 10
- 231100000350 mutagenesis Toxicity 0.000 abstract description 10
- 102100030886 Complement receptor type 1 Human genes 0.000 abstract description 9
- 102000006834 complement receptors Human genes 0.000 abstract description 9
- 108010047295 complement receptors Proteins 0.000 abstract description 9
- 230000003190 augmentative effect Effects 0.000 abstract description 6
- 238000012512 characterization method Methods 0.000 abstract description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
- 101150107440 crl gene Proteins 0.000 description 110
- 230000000694 effects Effects 0.000 description 91
- 235000018102 proteins Nutrition 0.000 description 79
- 235000001014 amino acid Nutrition 0.000 description 72
- 229940024606 amino acid Drugs 0.000 description 67
- 230000035772 mutation Effects 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 230000006870 function Effects 0.000 description 20
- 239000003446 ligand Substances 0.000 description 17
- 102100039373 Membrane cofactor protein Human genes 0.000 description 15
- 102100032768 Complement receptor type 2 Human genes 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 13
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000004074 complement inhibitor Substances 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 101710184994 Complement control protein Proteins 0.000 description 5
- 229940124073 Complement inhibitor Drugs 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 102000016550 Complement Factor H Human genes 0.000 description 4
- 108010053085 Complement Factor H Proteins 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 3
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001504519 Papio ursinus Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 108010078804 Classical Pathway Complement C5 Convertase Proteins 0.000 description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101710121996 Hexon protein p72 Proteins 0.000 description 2
- 101000740685 Homo sapiens C4b-binding protein alpha chain Proteins 0.000 description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710146216 Membrane cofactor protein Proteins 0.000 description 2
- 108700005084 Multigene Family Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001295 alanines Chemical class 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000052964 human C4BPA Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 239000012570 Opti-MEM I medium Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101150039984 RCA gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 102000046508 human CR1 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BOARIOLZPFSAQJ-NQSKQZERSA-N katacalcin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](OC)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)C(CC=1NC=NC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 BOARIOLZPFSAQJ-NQSKQZERSA-N 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031978 negative regulation of complement activation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to modified forms of complement regulators derived from regulatory proteins of complement activation (RCA), especially CRl.
- RCA complement activation
- the complement system serves to aid in the removal of foreign substances and of immune complexes from animal hosts. This system and its regulation is reviewed by Hourcade, D., et al., Advances in Immunol (1989) 45:381-416. Briefly, the complement system generates, either by a "classical pathway” or an “alternative pathway,” C3b which binds to target immune complexes or foreign substances and marks them for destruction or clearance. C3b is generated from its precursor C3 by the proteolytic enzymes collectively designated "C3 convertase.” One form of C3 convertase is generated in the classical pathway by the association of the proteins C4b and C2a. The other form is generated in the alternative pathway by association of C3b and Bb.
- Both C3 convertases can associate with an additional C3b subunit to form the C5 convertases, C3bBbC3b and C4bC2aC3b, both of which are active in the production of the C5-C9 membrane attack complex which can cause cell lysis, and the production of C5a, a major pro-inflammatory agent.
- C3b and less directly, C4b
- C3b are agonists in the complement system.
- the complement system is regulated via a number of interrelated mechanisms. There are two general mechanisms for inhibition of the destructive components of the complement system.
- the first mechanism is generally reversible, facilitating the dissociation of the C3 convertases— i.e., C3b from Bb and C4b from C2a.
- Facilitation of dissociation is sometimes known as decay acceleration.
- the dissociation may also involve reversible binding of the antagonist proteins to C3b or C4b components, thus preventing their reassociation.
- the other mechanism which is an irreversible inactivation process, results from proteolytic cleavage of the C3 convertase components C3b or C4b by the serine protease factor I.
- This proteolytic cleavage occurs only in the presence of a cofactor.
- Both general regulatory mechanisms, the facilitation of dissociation of C3b and C4b and the inactivation of C3b and C4b through cleavage by factor I also apply to the inhibition of the alternative pathway C5 convertase (C3bBbC3b) and the classical pathway C5 convertase (C4bC2aC3b).
- the proteins encoded by a region of the genome which is designated the "regulators of complement activation” (RCA) gene cluster are involved in both of these pathways.
- RCA regulatory of complement activation
- Evaluation of the comparative sequences of CRl, CR2, DAF, MCP, C4bp, and factor H has established that the RCA proteins are organized into short consensus repeat ("SCR") containing and non-SCR-containing regions.
- SCR repeats are composed of 60-70 amino acid and share a number of invariant or highly conserved amino acid residues with other SCRs in the same protein or SCRs in other family members.
- Those members of the family which are membrane bound also have at their C termini either transmembrane regions and intracellular regions or a glycolipid anchor.
- the SCRs form the extracellular portions of those members of the family which are membrane-bound and almost all of the protein structure in the secreted members.
- C4b-binding activity C3b-binding activity
- C4b cofactor activity C4b cofactor activity
- C3b cofactor activity C4b cofactor activity
- C3b cofactor activity C4b cofactor activity.
- Cofactor activity requires binding but binding alone may not be sufficient for cofactor activity.
- CRl C4b binding and cofactor activity requires SCRs 1, 2 and 3, 8, 9, and 10, or 15, 16, and 17, which are corresponding regions of the protein.
- C3b binding and cofactor activity requires SCRs 8, 9, and 10, or 15, 16, and 17, which are corresponding regions of the protein.
- the multiple binding sites of CRl can cooperate in their interactions with C3b-containing targets.
- CRl binds C3b-C3b dimers much more tightly than C3b monomers because binding to dimers can occur simultaneously at two sites in the same CRl molecule, as reported by Wong and Farrell, J. Immunol. 146:656 (1991); Ross and Medof Adv. Immunol. 37:217 (1985)).
- the C5 convertases which are important in the stimulation of inflammation and in lysis of some target cells, are composed of multiple CRl ligands:
- the classical C5 convertase contains C3b and C4b (C4bC3bC2a) while the alternative pathway C5 convertase contains two C3b proteins (C3bC3bBb).
- Inactivation of the C5 convertases by CRl can also involve cooperation between more than one CRl binding site. Wong and Farrell J. Immunol. 146:656 (1991) showed that more than one CRl C3b binding site may be essential for effective inhibition of alternative pathway C3 and C5 convertases.
- Human CD35 [complement receptor type 1 (CRl), C3b/C4b or immune adherence receptor] is a type 1 transmembrane glycoprotein.
- CCPs complement control protein repeats
- SCRs short consensus repeats
- Figure 1 All but the two carboxyl terminal CCPs are organized into four larger units, called long homologous repeats (LHR), each seven CCPs long, Hourcade D., et al. I Exp Med 168:1255-70 (1988) and Vogelstein, L.B., et al. J Exp Med 165:1095-112 (1987).
- the number of LHRs varies from three to six among allotypes, leading to their size variation.
- the allotypes A or F (frequence of 0.82), B or S (0.16), C or F (S0.01) and D ( ⁇ 0.01) have an Mr of 220, 250, 190 and 280 k under reducing conditions on 5% SDS- PAGE, respectively, Holers, V.M., et al. Proc Natl Acad Sci USA 84:2459-63 (1987), Van Dyne S., et al. Clin Exp Immunol 68:570-9 (1987), and Wong, W.W., et al J Exp Med 169:847-63 (1989).
- a new nomenclature, along the lines of that utilized for other complement proteins, has been recommended (Table 1).
- CD35 binds C3b and C4b with a high affinity and iC3b with a lower affinity.
- the number of C3b binding sites depends on the allotype and varies from one in type C to four in type D, Wong, W.W. 1 Tnvest Dermatol 94:64S-7S (1990).
- Each of these highly homologous interactive sites also binds C4b but with approximately a log lower affinity than for C3b.
- Repeats 1-3 bind C4b with barely detectable C3b binding capability.
- the affinity for dimeric and polymeric C3b increases with the number of binding sites, Wong, W.W., et al. J Immunol 146:556-62 (1990).
- CR1/CR2 chimeric receptors in which various short consensus repeats (SCRs) of CRl were attached to CR2 were transiently expressed on COS cells.
- SCRs short consensus repeats
- K562 cells were stably transfected with wild-type CRl, deletion mutants of CRl, and the CR1/CR2 chimeras, respectively, and assayed for binding of 125I-pC3b.
- the dissociation constants (Kd) for pC3b of wild-type CRl and the LHR-BD and -CD constructs were in the range of 1.0-2.7 nM, and of the CR1/CR2 chimeras containing SCRs 1-4, 1-3, and 2-4 of LHR-B or -C were 1.8-2.4, 6-9, and 22-36 nM, respectively.
- the factor I-co factor function of the CR1/CR2 chimeras paralleled the C3b-binding function of the constructs.
- a CRl/immunoglobulin (Ig) chimeric protein prepared by fusing SCRs 1-4 of LHR-B to the heavy chains of a murine F(ab')2 monoclonal antibody was as effective as soluble, full-length CRl in binding pC3b, serving as a cofactor for factor I-mediated cleavage of C3b, and inhibiting activation of the alternative pathway, indicating that the bivalent expression of these SCRs reconstitutes the alternative pathway inhibitory function of CRl.
- PCT US94/ 10820 by Washington University entitled "Modified Truncated Complement System Regulators" describes a number of site specific mutations of CRl that alter activities. However, the effects of the different mutations have been determined to be unique and it is therefore still desirable to provide additional modified forms and information regarding changes that can be made to CRl to alter its biochemical and biological properties.
- CRl complement receptor type 1
- CD35 Two functionally distinct but homologous sites in complement receptor type 1 (CRl) (CD35) were characterized by homologous substitution mutagenesis of two CRl derivatives, each containing one site specific mutation. In both sites, reducing negative and/or increasing positive charge augmented interaction with iC3/C3b and C4b, supporting a role of ionic forces in the binding reaction.
- substitution of Asp at the end of complement control protein repeat (CCP) 2 with an Asn transformed the protein with negligible cofactor activity and iC3 binding into a mutant with activities similar to native CRl. Consequently, this protein, one-fourth the size of CRl, is a therapeutic candidate for a complement inhibitor.
- CCP complement control protein repeat
- FIG. 1 is a schematic representation of CRl derivatives and theirTjind ⁇ g'domains: Extramembraneous part of CRl is composed of 30 CCP (shown as boxes). Based on degree of homology, the first 28 CCP can be organized into LHR A, B, C and D, each seven CCP long, having arisen by duplication of a seven CCP unit. There are two distinct functional sites composed of three CCP.
- SITE 1 is located in LHR A.
- Two nearly identical copies of SITE 2 are present in LHR B and C.
- the first two CCP in SITE 1 (CCP 1 and 2) are distinct (about 40%) different) from the first two CCP in SITE 2 (CCP 8 and 9) and they are marked by different shading.
- the last CCP in both sites varies by only one amino acid and is represented by a black box.
- Figure 2 is a schematic of the mutations in CCP 1 and in CCP 2 of LHR A. Amino acids in CCP 1 are aligned with those in CCP 8 and the amino acids in CCP 2 are aligned with those in CCP 9. For CCP 8 and 9 only amino acids different from those in CCP 1 and 2 are shown. The four invariant cysteines per CCP are boxed. Key mutations T ⁇ 4 , N 2 and D ⁇ o are in bold type. Multiple amino acid substitutions are identified by the numbers above the braces. The single amino acid substitutions 14a-j, 15a and b, and lOa-d, are indicated by the italicized letters below the alignment while those described in the prior art are in regular font.
- C4b above the alignment refers to the amino acid in SITE 1 necessary for interaction with C4b.
- C3b and “C3b/C4b” below the alignment indicate the amino acid in SITE 2 which, if transferred to SITE 1, increase its interaction with C3b or C3b and C4b, respectively.
- the subscript that precedes the first amino acid and the one that follows the last amino acid in a CCP indicate amino acid number in the mature CRl .
- Figure 3 is a graph of the effect on iC3 binding (percent) of substitutions of D ⁇ 0 in CCP 2 as a function of salt concentration (mM NaCl).
- Figure 4 is a schematic of mutations in CCP 10 of CRl. Amino acids in CCP 10 of CRl are aligned with those of CCP 3 of CR2. The invariant cysteines are boxed. Amino acids in CCP 10 of CRl were changed, initially a few and subsequently one at a time, into their counterparts in CCP 3 of CR2. Multiple amino acid substitutions are identified by the numbers above the braces and single amino acid changes by letters below the alignment. Because the numbering was initiated in earlier work in which mutants 1-15 were constructed (Krych, et al. 1991, 1994), the new mutants start with #16. In order not to introduce deletions, gaps in the CR2 sequence were filled with alanines in mutants 21, 23 and 25.
- CCP 17 differs from CCP 10 only in that in sequence 21 L ⁇ o56 and R ⁇ 05 replace P606 and G60 , respectively, (as shown under the alignment).
- the subscript that precedes the first amino acid and the one that follows the last amino acid in a CCP indicate the amino acid number in the mature CRl .
- Figures 5a and 5b are graphs of the effect of mutations in CCP 10 on binding to iC3 ( Figure 5a) and C4b ( Figure 5b).
- modified CRl analogs can be used to modulate the complement system by altering the binding specificity of the protein in both membrane-bound and soluble forms.
- CCP complement control protein repeats
- DAF decay accelerating factor
- MCP membrane cofactor protein
- Factor H has three binding sites for C3b in a single polypeptide chain composed of 20 CCP (Sharma, et al. Proc. Nail. Acad. Sci. USA 93, 10996-11001 (1996)). Each site is different and only one has cofactor activity (CA).
- Human C4b binding protein contains seven copies of a single site as a result of joining seven identical protein chains by disulfide bonds (Chung, et al. Biochem. J. 230, 133 (1985)).
- Complement receptor type 1 (CRl; CD35) represents yet another way of increasing the number of active sites.
- RCA proteins interact with their ligands via CCP.
- CCP protein-protein interactions
- DAA decay accelerating activity
- CA decay accelerating activity
- CCPs complement control protein repeats
- CD55 decay- accelerating factor
- CD46 membrane cofactor protein
- CD55 decay- accelerating factor
- CD46 membrane cofactor protein
- Factor H has three binding sites for C3b in a single polypeptide chain composed of 20 CCPs. Each site is different, and only one has cofactor activity.
- Human C4b-binding protein contains seven copies of a single site as a result of joining seven identical protein chains by disulfide bonds.
- Complement receptor type I represents yet another way of increasing the number of active sites.
- CR1(CD35) represents yet another way of increasing the number of active sites.
- CCPs present in the most common allelic form of CRl all but the two carboxyl-terminal CCPs can be organized into four long homologous repeats (LHRs), termed A, B, C, and D, each seven CCPs long.
- LHRs long homologous repeats
- modified proteins described herein are collectively referred to as "modified CRl analogs".
- Trusted proteins are typically modified to remove the C-terminal regions which effect membrane binding or secretion and sometimes modified further by deletion of one or more CCPS.
- Hybrid proteins are composed of portions, i.e., the CCPS, of one RCA protein combined with CCPs of one or more other RCA proteins.
- Recombined forms are those wherein the CCPs of an RCA protein are rearranged in a new order.
- Modified RCA proteins include proteins which result from combinations of these changes. In some embodiments, modifications are made using corresponding CCPs of the protein as sites for alteration.
- corresponding CCP is meant the most highly homologous CCP as determined by comparison of the amino acid sequences of the protein. Exon structure can in some cases facilitate this assignment.
- CCPs 1-3 of CRl correspond to CCPs 2-4 of DAF.
- CCPs 1-3 of factor H, CRl, C4bp and MCP correspond.
- CRl is organized into a series of long homologous repeats (LHRS) containing 7 CCPs so that CRl CCPs 1-7 correspond to CRl CCPs 8-14; 15-21; and 22-2S " ;
- CR2 is organized into a se ⁇ es of long homologous repeats of 4 CCPs in length.
- CCPs 1-2 of CRl correspond to CCPs 3-4, CCPs 7-8, CCPs 11-12 and CCPs 15-16 of CR2.
- SITE 1 is located in CCP 1-3 of LHR A.
- SITE 2 is in CCP 8-10 of LHR B and its nearly identical [different by only three amino acids (aa)] copy is in CCP 15-17 of LHR C.
- SITE 1 binds mainly C4b (Klickstein, et al., (1988); Krych, et al., (1991); Krych, et al., (1994); Reilly, et al., J. Biol. Chem. 269, 7696- 7701 (1994)). It has barely detectable cofactor ("CA”) for cleavage of C4b and C3b.
- CA cofactor
- Epitopes were also mapped for a blocking and a function enhancing monoclonal antibody. Their effects can be explained by epitope location.
- the first antibody binds near functionally important residues.
- the second may shield inhibitory (negatively charged) residues.
- Regulators of complement activation interact with their ligands via CCPs.
- CCPs proteins of the regulators of complement activation family
- over 40 other proteins possess CCPs which in many cases also participate in protein-protein interactions.
- the functions of CRl namely ligand binding, decay-accelerating activity, and CA, result from the interaction of CCPs with C3b and C4b.
- understanding CRl function requires elucidation of structure- function relationships between CCPs and their ligands.
- Mutant 10a is a candidate for a complement inhibitor smaller than sCRl but with a similar activity.
- baboon CRl contains a modified SITE 1 which has K 27 and N 1 0 9 and each of these two amino acids confers properties of SITE 2 on SITE 1 ( ⁇ inriingham, et al., J. Immunol. 157, 2586-2892 (1996)).
- This short form is the only CRl expressed by baboon E and it contains just SITE 1 (CCP 1-8) and yet has activities of both human sites. Chimpanzee (Subramanian, et al., J. Immunol.
- CRl has only SITE 1 (CCP 1-6).
- CCP 1-6 the two amino acids by which it differs from human SITE 1 are present in the homologous position of human SITE 2. If they are placed in SITE 1, it acquires C3b binding.
- a modified SITE 1 may serve as its functional equivalent (Subramanian, et al., 1996). Moreover, it only requires one or a few amino acid substitutions at homologous positions to acquire the necessary functional activity. Further, two distinct sets of substitutions can accompUsh this end, either as per the 10a and baboon proteins or the one used by the chimpanzee protein.
- the activity of SITE 1 and SITE 2 is increased if negative charge is reduced and/or positive charge enhanced at key positions.
- activity of SITE 1 is increased by replacing T] 4 ,N 29 , D ⁇ 09 or Eu 6 (mutant 1 lc in Ref 11) with their homolog in SITE 2, either K or N.
- additional substitutions indicated that its negative charge inhibits interaction of SITE 1 with iC3.
- Activity of SITE 2 was also increased as a result of higher positive charge.
- One example is the greater binding of iC3 and C4b by LHR C than by LHR B (instead of G «>7 in CCP 10 of LHR B there is an R1059 in CCP 17 LHR C).
- Each of the sequences comprising mutants 10/11 and 14 in SITE 1 has three negatively charged amino acids while the corresponding peptides in SITE 2 have one or none. Interchanging these sequences increases activity of SITE 1. Moreover, the enhancing effect of mAb 8C9.1, which recognizes sequences 14 and 15 and confers iC3/C3b and increases C4b binding, might be explained by blocking negatively charged amino acids. These data suggest that the first half of CCP 1 may reduce ligand binding of SITE 1. Overall, the hypothesis is that CRl binds C3 and C4 through ionic interactions with positive charges in the active sites of CRl playing a key role.
- Y 5 % may be a contact point with both C3b and C4b. This is consistent with absence of Y in the homologous, but presumably nonfunctional, CCP 24. Other contact point(s) for both ligands are likely to be in sequence 22 and/or 21 ( Figure 5 a and b, Table III and IV). Although as noted, interactions of CCP 10 with iC3/C3b and C4b are very similar, they are not identical. That the differences do exist is based, for example, on mutant 17 which has CA for C3b but no CA for C4b and on mutant 19 with C4b binding capability but very poor iC3 binding. Similar observations have been made for MCP (Adams, et al., I. Immunol. 147, 3005-3011 (1991)) and DAF (Coyne, et al, I. Immunol. 149, 2906- 2913 (1992)), suggesting that the C3b and C4b sites, although overlapping, have distinctive features.
- amino acid sequences essential (or refractory) to binding to C4b and C3b and C4b and C3b cofactor activity permits transposition of similar sequences into corresponding regions of the same protein or corresponding regions of other family members or alteration of sequences which bind C3b and C4b so as to alter their affinities.
- Corresponding regions have been identified by degree of amino acid sequence homology.
- CCPs 1-3, CCPs 8-10, CCPs 15-17 and CCPs 22-24 are CCPs 1-3, CCPs 8-10, CCPs 15-17 and CCPs 22-24.
- the CCP portions labeled 2-4 in DAF correspond to those labeled 1-3, 8-10, 15-17 and 22-24 for CRl.
- Substitution of portions of DAF with homologous CRl sequences provides forms of DAF with cofactor activity and/or binding activity, such as is exhibited by CRl.
- substitutions of portions of MCP with homologous sequences providerforms of MCP with increased binding affinity and cofactor activity and/or increased dissociation activity.
- the C3b and C4b binding and cofactor sequence in CRl can be transferred to corresponding locations or to locations referenced to conserved amino acids in alternative CCPs to confer C3b binding.
- the C4b binding regions are shown to be associated with separate critical locations in the CCPs of CRl. Alterations in amino acid sequences of the corresponding CCPs in CRl or in additional RCA family members or their truncated, hybrid, or recombined forms in these positions alter C4b binding and cofactor activities and in at least one case alter C3b binding and cofactor activities.
- Structurally, similar amino acids can be substituted in such transfers for some of the specified amino acids.
- Structurally similar amino acids include: (I,LN); (F,Y); (K,R); (Q, ⁇ ); (D,E); and (G,A).
- C3b or C4b cofactor activity can be enhanced by substitutions which increase the binding activity of the other factor, i.e., to increase C4b cofactor activity, amino acids are substituted into the modified protein which increase C3b binding and vice versa.
- the modified proteins described herein are most conveniently prepared using recombinant techniques, although in some cases they can be prepared by enzymatic cleavage, for example, to yield truncated or soluble forms of the naturally occurring proteins.
- the genes encoding the various members of the RCA protein family are of known sequence and are published. cDNA encoding CRl was described by Vogelstein, L.B., et al., J. Exp. Med. (1987) 165:1095, Vogelstein, L.B., et al., J. Exp. Med. (1988) 168:1699; Hourcade, D., et al., J. Exp. Med. (1988) 1 :1255.
- accession numbers for human CRl Swissprot: P17927; EMBL/GENBANK: Y00816 and X05309; PIR: S03843 and 28507.
- the availability of the cDNA sequence makes possible the preparation of genetic constructs encoding truncated forms and other modified forms of the proteins using standard site-directed mutagenesis techniques, such as those described by Kunkel, T.A., et al., Methods Enzymol (1987) 154:367-382.
- the modified gene is expressed using standard recombinant techniques.
- the gene sequence is ligated into a suitable expression vector under the control of sequences known to be appropriate to the desired host.
- Production of recombinant proteins in microbial systems such as E. coli, B. subtilis, various strains of yeasts, and other fungi, such as Aspergillus, is well known.
- Standard expression systems in various cell lines are well known and standard in the art.
- Transgenic animals can be constructed for several species.
- the gene is placed under the control of a suitable promoter, for example, the metallothionine promoter or a tissue specific promoter, and the gene microinjected into an embryo, which is then implanted into a surrogate mother.
- a suitable promoter for example, the metallothionine promoter or a tissue specific promoter
- Production in transgenic animals is important in the context of preparing transplants for use in other species.
- mice and rats for testing of genetic manipulation procedures
- larger animals such as pigs, cows, sheep, goats, and other animals that have been genetically engineered using techniques known to those skilled in the art. These techniques are briefly summarized below based principally on manipulation of mice and rats.
- Calcium phosphate/DNA precipitation, direct injection, and electroporation are the preferred methods. Direct injection results in a high efficiency of integration. Desired clones are identified through PCR of DNA prepared from pools of injected ES cells. Positive cells within the pools are identified by PCR subsequent to cell cloning (Zimmer and Gruss, Nature 338, 150-153 (1989)).
- DNA is prepared and analyzed by both Southern blot and PCR to detect transgenic founder (Fo) animals and their progeny (Fi and F 2 ). Once the transgenic animals are identified, lines are established by conventional breeding and used as the donors for tissue removal and implantation using standard techniques for implantation into humans. Purification of Analogs
- the analogs recombinantly produced in culture or animals can be purified from the cell culture using standard purification techniques such as chromatography, for example, immunoaffinity or ion-exchange chromatography, and electrophoresis, generally using the same procedures as have been published for use in purifying the naturally occurring material.
- standard purification techniques such as chromatography, for example, immunoaffinity or ion-exchange chromatography, and electrophoresis, generally using the same procedures as have been published for use in purifying the naturally occurring material.
- Affinity chromatography columns were prepared as described by Krych, et al., Proc. Natl. Acad. Sci. USA 88, 4353-4357. Binding assays were performed using 100 ml of iC3-Sepharose (iC3-S) or C4b-Sepharose (C4b-S) and 1.8 ml of medium containing of the mutant protein. Media were diluted to desired concentrations of NaCl. After 1 hr on a rotator at room temperature, samples were centrifuged, media removed and bound protein eluted from the Sepharose using 400 mM NaCl with 1% NP-40.
- Eluted proteins were quantitated by ELISA, using two monoclonal anti-CRl antibodies, 3D9 and El l (Hogg, et al., Eur. J. Immunol. 14, 236-240 (1984), O'Shea, et al., J. Immunol. 134, 2580-2587 (1985)). Since neither monoclonal antibody reacts with CRl CCPs-1,2,8 or 9, all of the mutants derived from either CRl -4 or CRl -4(8,9) could be quantitated using this assay. For each mutant protein at least three binding assays from different transfections were performed.
- C3 and C4 were purified according to the method of Dykman, et al., Proc. Natl. Acad. Sci. USA 80, 1698-1702 (1983), Dykman, et al., J. Exp. Med. 157, 2160-2165 (1983) or purchased (Quidel, San Diego, CA), converted to C3b and C4b and labelled with I using Iodogen coated beads (Pierce). Cofactor assays were performed using 200 ng of labelled C3b or C4b, 60 ng of factor I (Quidel) and media with mutant proteins.
- Complement activation can account for substantial tissue damage in a wide variety of autoimmune/immune complex mediated syndromes such as systemic lupus erythematosus, rheumatoid arthritis, hemolytic anemias, myasthenia gravis and others. Inhibition of the complement system is a desirable therapeutic intervention in these cases. In some instances, specific inhibition of the classical pathway alone by RCA analogs could be preferred since long-term inhibition of the alternative pathway could lead to side effects.
- Inhibition of complement activation could also be desirable in cases that involve tissue damage brought about by vascular injury such as myocardial infarction, cerebral vascular accidents or acute shock lung syndrome.
- the complement system may contribute to the destruction of partially damaged tissue as in reperfusion injury.
- Highly stringent inhibition of complement for relatively brief periods might be preferred in these instances and soluble RCA analogs designed for higher potency may prove especially useful.
- the proteins encoded by the RCA gene cluster can be prepared recombinantly and used in diagnosis and therapy for the regulation of the complement system.
- the problems of transplantation of xenografts are reviewed by Platt, J.L., et al., in Immunology Today (1990) 11:450-457.
- Evidence has accumulated that the immediate hyperacute rejection of discordant xenografts is caused by recipient complement activity.
- Transgenic animals expressing human complement regulators (such as DAF or MCP) on cell surfaces could be an abundant source of organs that would be protected from hyperacute rejection in human recipients.
- a soluble complement inhibitor could also play a role in protecting xenografts from complement-mediated rejection.
- Complement inhibition may also prove important in the prevention of xenograft rejection.
- Organs derived from animals transgenic for human DAF or MCP may be protected at least in part from complement-mediated hyperacute rejection by the expression of transgenic DAF or MCP on the cell surfaces of the xenograft.
- Animals transgenic for RCA analogs designed for higher potency may provide more successful xenografts. Soluble RCA analogs may also prove useful in protecting the transplant in the recipient.
- Erthrocyte CD35 functions as an immune adherence receptor. It binds, processes and transports C3b/C4b bearing immune complexes to the fixed phagocyte system in liver and spleen, Herbert, LA. Am J Kidney Dis 17:353-61 (1991), Nelson, R.A. Science 118:733-7 (1953), and Schifferli, J.A., et al. Kidney Int 35:993-1003 (1989). Some microorganisms become coated with C3b, for example Lefshmama, Mycobacterium? ana HIV, and then use CD35 to enter host cells, Cooper, N.R. Immunol Today 1991; 12:327-31, and Thieblemont, N., et al.
- CD35 mediates a resette phenomenon between Plasmodium falciparum infected erythrocytes and normal erythrocytes, a marker of severe malaria, Rowe, J.A., et al. Nature 1997; 368:292-5. Accordingly, these CRl analogs may be useful in treating autoimmune diseases or infections with viruses or parasitic infections.
- Soluble analogs having decreased activity may also be useful as competitive inhibitors of the natural inhibitors, in cases where an increased complement mediated response is desirable or where an individual has a disorder in which their immunity is compromised by overproduction of the natural inhibitors.
- Recombinant soluble (stop codon placed before transmembrane domain) CRl inhibits unwanted complement activation in autoimmune diseases, Piddlesden, S.J., et al. J Immunol 1994; 152:5477-84, and Piddlesden, S.J., et al. J Neuroimmunology 1996; 71:173- 7. It also reduces complement induced tissue damage in conditions such as ischemia/reperfusion injury and prevents hyperacute xenograft rejection, Mulligan, M.S., et " al. J Immunol 1992; 148:1479-85, Pruitt, S.K., et al.
- the most desirable analogs based on the in vitro assays are tested in vivo.
- the in vitro assays are accepted as highly activity.
- the appropriate dosages are determined by comparing the in vitro activity of the naturally occurring protein with that of the analog, comparing the in vitro activity of the naturally occurring protein with the in vivo activity of the naturally occurring protein, then calculating the expected in vivo activity of the analog, adjusting for any measured differences in half-life.
- the analogs can be administered locally or systemically in pharmaceutically acceptable carries such as saline, phosphate buffered saline, or a controlled release formulation.
- dosage level and mode of administration of the analogs depend on the nature of the analog, the nature of the condition to be treated, and the history of the individual patient.
- Systemic administration is generally required, which may be by injection or by transmucosal or transdermal delivery. Administration by injection may be intravenous, intramuscular, intraperitoneal or subcutaneous.
- Formulations for injection are generally biocompatible solutions of the active ingredient such as Hank's solution or Ringer's solution.
- Formulations for transdermal or transmucosal administration generally include penetrants such as fusidic acid or bile salts in combination with detergents or surface-active agents. The formulations can then be manufactured as aerosols, suppositories, or patches. Oral administration is generally not favored for protein or peptide active ingredients; however, if suitably formulated so as to be protected from the digestive enzymes, oral administration can also be employed.
- penetrants such as fusidic acid or bile salts in combination with detergents or surface-active agents.
- the formulations can then be manufactured as aerosols, suppositories, or patches.
- Oral administration is generally not favored for protein or peptide active ingredients; however, if suitably formulated so as to be protected from the digestive enzymes, oral administration can also be employed.
- Suitable formulations for a desired mode of administration can be found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA. The dosage levels and precise formulations are obtainable by routine optimization procedures as is generally known in the art. Diagnostic Applications
- the analogs which are capable of binding C3b and/or C4b are useful as diagnostic tools in assessing the presence, absence or amount of C3b or C4b or C3b/C4b-bearing immune complexes in biological fluids.
- Such assays take advantage of the ability of the analog specifically to bind C3b and/or C4b and can be conducted in a variety of formats as is generally known. Formats for specific binding partner assays include direct and competitive formats, sandwich assays, and agglutination assays. Complexation between members of the specific binding pair can be conducted in solution or on a solid phase and can be detected using a variety of labeling techniques including fluorescence, radioisotopes, chromophores, and visible particles.
- Typical reagent kits useful in assays for C3b and/or C4b and/or C3b/C4b-bearing immune complexes include the analog specifically binding to the analyte, optionally coupled to a solid support and additional labeling reagents useful in the assay.
- one of many formats for the assay might include treating the sample to be tested with a solid support to which is coupled the analog as a specific binding partner, washing the support which has been treated with sample suspected of containing analyte, and then treating the washed support with anti-C3b or anti-C4b antibody labeled with an enzyme such as horseradish peroxidase.
- an enzyme such as horseradish peroxidase.
- the presence of labeled enzyme on a support is detected by addition of a substrate solution which results in the development of a color in the presence of the enzyme.
- mutants were made by oligonucleotide directed mutagenesis using Muta-Gene Ml 3 in vitro Mutagenesis Kit (Bio-Rad, Hercules, CA), MorphTM Plasmid DNA Mutagenesis (5 Prime ⁇ 3 Prime, Boulder, CO) or QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene). Only the first method requires a single stranded vector and a subcloning step. In the other methods, mutagenesis was performed directly in the double stranded plasmid without subcloning.
- LHR B was obtained from LHR A by changing amino acids in CCP 1-3 into those present in CCP 8-10 (Krych, et al., J. Biol. Chem. 269, 13273-13278 (1994)).
- the construct CCP 1-3 was made by replacing 195 th amino acid (the fourth position after the last C of CCP 3) in the protein LHR A with a STOP codon.
- the construct 8-10 was made by replacing 645 th amino acid (the fourth position after the last C of CCP 10) in the protein LHR B with a STOP codon.
- the strategy for homologous substitution mutagenesis of CCP 1 and 2 in LHR A was described by Krych, et al., (1991) and (1994) and is shown in Figure 2.
- LHR C Construction of LHR C.
- CRl cDNA in Ap r M8 obtained from Lloyd Vogelstein (Harvard Medical School, Boston, MA), served as a template for PCR amplification of the signal peptide and of CCP 15-21 (LHR C).
- 5' primer for amphfication of the signal peptide ATA TAC AGATCT ATG GGA GCC TCT TCT CCA AGA, introduces an upstream Bgi ⁇ site (underlined) for cloning to the expression vector pSG5 (Stratagene).
- the 3' primer ACA GTG ACC TAG GCC CCA TGC AAC TGG TAG CGC AAG CA introduces five silent mutations to generate Avrll site (underlined) for Ugation to LHR C and to disrupt GC rich stretches.
- the 5' primer, ATA TCT ATC ATC CTA GGT CAC TGT CAA GCA CCA was used. It includes codons for four amino acids between the last cysteine of CCP 14 and the first cysteine of CCP 15. Due to three silent substitutions, it creates an Avrll site (underUned) and interrupts sequence of four C nucleotides.
- the 3' primer for LHR C includes codons for five out of six amino acids between the last cysteine of CCP 21 and the first cysteine of CCP 22 followed by translation STOP codon and Bgi ⁇ site (underUned).
- Each PCR product was subcloned into TA cloning vector (Invitrogen, San Diego, CA), sequenced and cut out with Avrll and Bgi ⁇ . The signal peptide and LHR C fragments were then ligated through AvrH site and the hgation product cloned into Bgi ⁇ site of pSG5.
- CRl derivatives in COS 7 cells. Plasmids with cDNA encoding CRl derivatives were transfected into COS 7 cells using Lipofectamine (Life Technologies, Grand Island, NY) according to manufacturer's procedure. Twenty four h after the transfection, cells were washed and OPTI-MEM I medium without serum was added to avoid possible CA in bovine serum. After 48 to 72 h incubation supematants were collected, aUquoted and stored at -70° C until use.
- Binding assays A modification of the previously described procedure was used (Krych, et al. 1991). iC3 and C4b, isolated as described (Dykman, et al., Proc. Natl. Acad. Sci USA 80, 1698-1702 (1983); Dykman, et al., J. Exp. Med. 157, 2160-2165 (1983)), were coupled at 1 mg/ml to cyanogen-bromide activated SepharoseTM (SepharoseTM 6B, Pharmacia LKB Biotechnology Inc., Piscataway, NJ). iC3, C3 with a disrupted thioester bond, has the same reactivity with CRl as does C3b.
- iC3- or C4b-SepharoseTM iC3-S or C4b-S
- medium 1 ml
- the columns were washed with 850 ⁇ lieftap ropria y dffale -PSS " containing 1% NonidetTM P-40 and the proteins bound to iC3-SepharoseTM or C4b- SepharoseTM were eluted with 1 ml of 300 mM NaCl containing 1% NonidetTM P-40.
- the levels of CRl derivatives in the eluates were determined by sandwich ELISA using mAb 3D9 (O'Shea, et al, J. Immunol. 134, 2580-2587 (1985)) coated wells and mAb El 1 (a gift from Ronald Taylor, University of Virginia School of Medicine, Charlottesville, VA) (Hogg, et al., Eur. J. Immunol. 143, 236-243 (1984)), conjugated to horse radish peroxidase.
- 3D9 a rabbit polyclonal Ab to human CRl (Makrides, et al., J. Biol. Chem. 267, 24754-24761 (1992)) was used.
- Results are expressed as percent of CRl derivative bound to iC3-S or C4b-S of that initially offered to the SepharoseTM.
- Effect of mAb 8C9.1 (a gift from Henry Marsh, T Cell Sciences, Inc., Needham, MA) on Ugand binding was analyzed in the binding assay described above.
- the medium containing the CRl derivative and the mAb (1 ⁇ g/ml) was added to the SepharoseTM affinity columns. Mapping 8C9.1 and 3D9 epitopes.
- the 8C9.1 epitope was mapped by ELISA in which wells were coated with 3D9.
- Bound LHR A derivatives were then detected with biotinylated 8C9.1 followed by horse radish peroxidase conjugated to extravidin (Sigma Chemical Co., St. Louis, MO). The reduced binding (to mutants 14e and 15a) was assessed by comparing the results of this assay with the standard ELISA which uses El 1 as a detection Ab.
- the 3D9 epitope was mapped by standard ELISA in which wells were coated with 3D9 and Ell was used to detect bound proteins.
- the reduced binding (to mutants 20d and 22a) was measured by comparing these results with those in which wells were coated with polyclonal Ab and El 1 served as a detection Ab.
- C3b and C4b were biotinylated by incubating 125 ⁇ g of C3b or C4b with 3.4 ⁇ g of NHS-LC biotin (Pierce, Rockford, IL) for 1 h at room temperature followed by removal of linincorporated biotin on MicroconTM 30 microconcentrators (Amicon, Beverly, MA).
- Biotinylated C3b or C4b 250 ng were mixed with 50 ng of factor I (Advanced Research Technologies) and with medium from transfected cells containing 0.002 pmoles of a CRl derivative in 25 mM NaCl.
- the cofactor protein was limiting reagent in this assay system.
- the three initial CCP of LHR A, B and C are functional if attached to irrelevant CCP of CRl or to an unrelated protein (Klickstein, et al., J. Exp. Med. 168, 1699-1717 (1988); Kalli, et al, 1991)). Proteins composed only of CCP 1-3 or CCP 8-10 were tested. The specificity of binding was identical to the parental proteins in that CCP 1-3 bound C4b and CCP 8-10 bound C4b and C3b. Ligand binding was reduced by 10-30% 2 as compared to their parental proteins LHR A and LHR B.
- CA for C3b and C4b was increased in mutant 14a but not detectably changed in mutants 14b-j.
- mutant 15b the change of N 29 ⁇ K (mutation 15b) accounted for all of the enhanced iC3 and C4b binding (Table I) and CA for C3b and C4b observed in mutant 15.
- the other mutation, Y 27 ⁇ S (mutant 15a) had no effect (Table I).
- mAb 8C9.1 recognizes CCP 1 and enhances iC3 and C4b binding by LHR A. Of20 mAb to CRl tested (Nickells, et al. Clin. Exp. Immunol. 1998), 8C9.1 was the only one specific for LHR A, suggesting that its epitope is in CCP 1 or 2. By testing LHR A deleted of CCP 1 or 2, the 8C9.1 epitope was localized to CCP 1 (Table II).
- the epitope is in CCP 3 and 10 because deletion of CCP 3 or CCP 10 from LHR A or LHR B, respectively, abrogates 3D9 binding (Table V). To map the epitope more precisely, mutants in CCP 10 were tested. Mutants 20, 21 and 22 did not bind 3D9 (Table V). Within sequence 20, only mutation Rr ⁇ S (20f) abrogated 3D9 binding. Mutation S 598 - L (20a) and P 620 -s»K (22a) reduced binding by approximately 50%.
- LHR B Comparison of LHR B with LHR C.
- the copy of SITE 2 present in LHR C differs by three amino acids from the one in LHR B.
- One difference is in CCP 9 and 16 and it was demonstrated earlier that it has no effect on binding or CA (see mutant 10b(r) in Krych, et al. 1994).
- the other two amino acids differences are between CCP 10 and 17, specifically within peptide 21 (Fig. 4).
- CCP 17 Lios ⁇ a d R ⁇ 059 are present instead of P ⁇ o ⁇ and Gor ⁇ , respectively, in CCP 10.
- LHR B and C were compared.
- LHR C binds iC3 and C4b 10-40% more efficiently at 12.5 - 100 mM ⁇ aCl.
- iCa binding was performed at 12.5, 25, and 100 M NaCL C4b bindine waa performed at 12.5, 26, and 60 mM N ⁇ Cl. Protein quantification * « ⁇ s by ELISA. Eeaulta at 25 mM NaCl are shown. In all tables, % binding refers to the fraction of a CRl derivative offered to iC3-S (or C4b-S) that bound to it.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44521/00A AU4452100A (en) | 1999-04-09 | 2000-04-07 | Modified complement system regulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12852099P | 1999-04-09 | 1999-04-09 | |
US60/128,520 | 1999-04-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000061752A2 true WO2000061752A2 (en) | 2000-10-19 |
WO2000061752A3 WO2000061752A3 (en) | 2001-01-18 |
WO2000061752A9 WO2000061752A9 (en) | 2002-06-20 |
Family
ID=22435737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/009288 WO2000061752A2 (en) | 1999-04-09 | 2000-04-07 | Modified complement system regulators |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4452100A (en) |
WO (1) | WO2000061752A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005479A1 (en) * | 2003-05-09 | 2005-01-20 | University Of Massachusetts | Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor |
US20120226020A1 (en) * | 2004-01-21 | 2012-09-06 | Medof M Edward | Hybrid and chimeric polypeptides that regulate activation of complement |
US11524050B2 (en) | 2018-01-15 | 2022-12-13 | Complement Therapeutics Limited | C3B binding polypeptide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0512733A2 (en) * | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
WO1995008343A1 (en) * | 1993-09-24 | 1995-03-30 | Washington University | Modified truncated complement system regulators |
-
2000
- 2000-04-07 WO PCT/US2000/009288 patent/WO2000061752A2/en active Application Filing
- 2000-04-07 AU AU44521/00A patent/AU4452100A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0512733A2 (en) * | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
WO1995008343A1 (en) * | 1993-09-24 | 1995-03-30 | Washington University | Modified truncated complement system regulators |
Non-Patent Citations (2)
Title |
---|
KRYCH M. ET AL.: "Analysis of the functional domains of complement receptot type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis" J. BIOL. CHEM., vol. 269, no. 18, 6 May 1994 (1994-05-06), pages 13273-13278, XP002144542 cited in the application * |
KRYCH M. ET AL.: "Structure-function analysis of the active sites of complement receptor type 1" J. BIOL. CHEM., vol. 273, no. 15, 10 April 1998 (1998-04-10), pages 8623-8629, XP002144541 cited in the application * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005479A1 (en) * | 2003-05-09 | 2005-01-20 | University Of Massachusetts | Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor |
US20120226020A1 (en) * | 2004-01-21 | 2012-09-06 | Medof M Edward | Hybrid and chimeric polypeptides that regulate activation of complement |
US8932601B2 (en) * | 2004-01-21 | 2015-01-13 | Case Western Reserve University | Hybrid and chimeric polypeptides that regulate activation of complement |
US11524050B2 (en) | 2018-01-15 | 2022-12-13 | Complement Therapeutics Limited | C3B binding polypeptide |
Also Published As
Publication number | Publication date |
---|---|
AU4452100A (en) | 2000-11-14 |
WO2000061752A9 (en) | 2002-06-20 |
WO2000061752A3 (en) | 2001-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2067653C (en) | Modified complement system regulator | |
US6096515A (en) | NF-AT polynucleotides | |
US20040236092A1 (en) | Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof | |
US5594120A (en) | Integrin alpha subunit | |
US5965396A (en) | Human lymph node derived GTPase | |
WO1997032020A2 (en) | Shc proteins | |
WO1997032020A9 (en) | Shc proteins | |
US6586577B2 (en) | Telomere repeat binding factors and diagnostic and therapeutic use thereof | |
JPH05178894A (en) | Peptide inhibiting ras-gap interaction | |
EP0665887B1 (en) | Human 5-ht 2? receptor | |
WO2000061752A2 (en) | Modified complement system regulators | |
AU691525B2 (en) | Modified truncated complement system regulators | |
WO1999055728A2 (en) | Ese genes and proteins | |
WO1998033819A1 (en) | Cellular receptors for subgroup c adenoviruses and group b coxsackieviruses | |
WO1999026980A1 (en) | Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators | |
US6638734B1 (en) | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto | |
WO2002094876A2 (en) | Methods and compositions for treating respiratory mucin production associated disease conditions | |
WO2000077207A2 (en) | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto | |
EP1493446A1 (en) | Modified truncated complement system regulators | |
WO2002077026A2 (en) | Gene involved in v(d)j recombination and/or dna repair | |
WO2004050702A2 (en) | Novel ifngamma-like polypeptides | |
CA2357987A1 (en) | Genetic sequence related to bone diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-39, DESCRIPTION, REPLACED BY NEW PAGES 1-45; PAGES 40-42, CLAIMS, REPLACED BY NEW PAGES 46-48; PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |